EXH.00 / OPENING PLATE
the aod-9604 record
A studio review of one hexadecapeptide: six human trials, two regulatory decisions, one quietly closed obesity programme, and a preclinical pivot into cartilage that never reached a human study.
The short version
AOD-9604 is a synthetic 16-amino-acid peptide — a hexadecapeptide — cut from the fat-metabolism end of human growth hormone. Scientists at Monash University built just that tail piece (residues 177–191) hoping to get the fat-burning activity without the rest of the hormone's biology. In fat cells it suppresses new-fat synthesis and, in obese mice, boosts the beta-3 adrenergic receptors that drive fat burning. It does not plug into the growth-hormone receptor, and it does not raise IGF-1. Here is the honest entry point: when it was tested in roughly 900 people for weight loss, the pivotal Phase IIb obesity trial did not beat placebo, and the obesity programme was shelved in 2007. The December 2024 FDA Pharmacy Compounding Advisory Committee also voted not to add it to the 503A compounding list. The safety record from six human trials is clean; the fat-loss record, in people, is not. What the research-use community reports — including the most common report of all, which is that nothing happened — is on the effects page.
What AOD-9604 is, in one paragraph
AOD-9604 is a synthetic 16-amino-acid peptide — a hexadecapeptide — designed to reproduce the fat-mobilising tail of human growth hormone without dragging along the rest of the hormone's biology. The sequence is the C-terminal lipolytic domain of hGH (residues 177-191) with an N-terminal tyrosine substituted in place of phenylalanine, and the two cysteines fold back on themselves through a disulfide bridge that mimics the parent hormone's cystine loop [1]. The molecule was built in the 1990s by Prof. Frank Ng's group at Monash University in Melbourne and developed clinically by Metabolic Pharmaceuticals Ltd. through six sequential trials between 2001 and 2007 [4][5][20]. It does not bind the growth hormone receptor, it does not raise IGF-1 at the doses studied, and it does not impair glucose tolerance — three properties that distinguish it sharply from intact hGH and which were the explicit design goals of the project [3][6][21].
Why a review site, and why now
There is a specific reason AOD-9604 attracts review-style searches in 2026, and it is not the same reason it attracted attention in 2007. The molecule arrived with a clean preclinical story, a credible separation-of-mechanism hypothesis, and a 12-week Phase IIa signal that looked promising on paper [4]. Then the pivotal 24-week Phase IIb (METAOD006, n=502) did not separate from placebo on primary endpoint, the obesity programme was discontinued, and the compound was repositioned toward an intra-articular cartilage-repair indication that produced exactly one published rabbit study before going quiet [5][9][17].
The modern review interest sits on top of two newer artefacts. The first is a self-affirmed GRAS designation for low-milligram oral nutraceutical use — an industry-led safety conclusion, not an FDA drug approval, and one that does not extend to the injectable or multi-milligram clinical doses sold by wellness clinics and online vendors [15]. The second is the December 4, 2024 vote of the FDA Pharmacy Compounding Advisory Committee, which declined to add AOD-9604 (either free base or acetate) to the 503A Bulks List — effectively closing legal U.S. pharmacy compounding for the peptide [14]. Reviewing AOD-9604 in 2026 means holding all of those threads at once: a clean mechanism, a failed pivotal, a sparse preclinical pivot, an industry safety position, and a regulator that has declined to bless the compounding route.
What the studio reviews
This site indexes the AOD-9604 evidence base as a series of discrete exhibits rather than a single narrative. Each page handles one face of the record.
The /research page walks the preclinical mechanism (β3-adrenergic-receptor upregulation, cAMP/PKA/HSL lipolytic cascade, GHR-independence), the six-trial Metabolic Pharmaceuticals programme (METAOD001 through METAOD006), the rabbit knee-osteoarthritis pivot (Kwon & Park 2015), and the post-mortem 2024 regulatory record [2][3][5][9][14]. The /dosage page maps every dose and route that has actually appeared in published research — preclinical rodent doses, IV escalation in Phase I, the oral capsule programme in Phase II, intra-articular injection in the rabbit OA model, and the milligram-per-serving GRAS nutraceutical level — without recommending any human regimen [1][2][8][9][15]. The /faq answers the comparative literature-review questions that bring readers here: does AOD-9604 work for weight loss, why did the Phase IIb fail, what changed in 2024, how does the molecule sit against WADA's growth-hormone-fragment category [5][14][16]. The /references page is the full citation index, sortable and filterable.
What this site is not
AOD-9604 Reviews is an independent editorial publication. It is not a clinic, it does not employ clinicians, and it does not sell, distribute, or recommend any product. The 'reviews' in the domain name refers to the publication's editorial activity — reviewing the published research record — not to consumer product reviews and not to clinical opinions. No physician on this site has examined any reader, and no part of this site should be read as medical advice or as encouragement to obtain or use AOD-9604 outside of a properly authorised research setting.
A practical consequence: when the rest of this site says 'AOD-9604 was studied at 500 μg/kg/day in obese Zucker rats,' it means that and only that — a description of what an investigator administered to a research animal in a peer-reviewed study, with the citation attached [1]. It is not a dose suggestion, and the difference matters because the regulatory record around this peptide is unusually crisp: the obesity programme is closed, the 503A compounding route is closed, the OA programme never reached a human trial, and the WADA prohibition is in force [5][14][16].